卵巢癌患者血浆miR-205、miR-212及miR-429的水平分析及意义

目的 探讨卵巢癌患者血浆miR-205、miR-212及miR-429水平,分析3者与卵巢癌临床病理学特征的关系。方法 收集本院收治的71例上皮性卵巢癌患者未经治疗前的血浆标本（上皮性卵巢癌组）,采用实时定量RT-PCR（qRT-PCR）法检测以上标本的miR-205、miR-212及miR-429水平,收集卵巢癌患者的临床病理学参数（年龄、临床分期、分化程度、组织类型及淋巴结转移情况）,比较不同miR-205、miR-212及miR-429水平的临床病理参数分布差异,采用受试者工作特征曲线（ROC）评价血浆miR-205、miR-212及miR-429水平在卵巢癌诊断中的临床价值。同时选取同期的68例女性健康体检者（健康对照组）及66例良性卵巢肿瘤患者（良性卵巢肿瘤组）的血浆标本作对照。结果 上皮性卵巢癌组的血浆miR-205水平高于良性卵巢肿瘤组和健康对照组,但miR-212和miR-429水平低于良性卵巢肿瘤组和健康对照组,差异均有统计学意义（P<0.05）;上皮性卵巢癌组中的miR-205水平与年龄、临床分期、分化程度及淋巴结转移有关,miR-212水平与临床分期、分化程度有关,miR-429水平与临床分期、淋巴结转移有关,以上差异均有统计学意义（P<0.05）;卵巢癌患者血浆miR-205水平与miR-212及miR-429均呈负相关（r=-0.572、-0.325）,miR-212与miR-429呈正相关（r=0.473）,差异均有统计学意义（P<0.05）;血浆miR-205、miR-212及miR-429诊断卵巢癌的AUC、灵敏度和特异度分别为0.915、92.1%和86.2%,0.944,87.3%和91.0%,0.905、88.5%和83.6%。结论 卵巢癌患者血浆中miR-205呈高表达,miR-212和miR-429呈低表达,与临床病理学参数有关,且在卵巢癌诊断中有一定的价值,可用于卵巢癌的辅助诊断和病情评估。     

血清miR-146a、miR-638水平与非小细胞肺癌患者化疗耐药性的相关性

目的 探讨血清微小核糖核酸(miR)-146a、miR-638水平与非小细胞肺癌(NSCLC)患者化疗耐药性的关系.方法 纳入化疗结束后产生耐药性的62例NSCLC患者作为耐药组,同期纳入接受化疗且化疗结束后未产生耐药性的62例NSCLC患者作为敏感组,全部患者均接受同步放化疗方案治疗,共治疗2个周期.回顾分析患者资料...     

卵巢癌组织中miR-29c、miR-133b和miR-1的水平分析及临床意义

目的 探讨卵巢癌组织中miR-29c、miR-133b和miR-1的表达水平,分析3者与卵巢癌临床病理特征的关系。方法 收集本院确诊的65例卵巢癌患者经手术切除的上皮性卵巢癌组织标本（卵巢癌组）,采用实时定量RT-PCR（qRT-PCR）法检测miR-29c、miR-133b及miR-1水平,收集对应卵巢癌患者的临床病理参数（年龄、临床分期、分化程度、组织类型及淋巴结转移）,同时选取32例正常卵巢上皮组织（正常组）和39例良性卵巢上皮囊肿组织（良性组）作对照,以正常组的各指标均数为界值,将卵巢癌组miR-29c、miR-133b及miR-1水平分为高水平组（＞正常组）和低水平组（≤正常组）,比较miR-29c、miR-133b及miR-1不同表达水平与卵巢癌临床病理参数的关系,同时分析卵巢癌组织中3者水平的关系。结果 卵巢癌组miR-29c水平高于正常组和良性组,而miR-133b和miR-1水平均低于正常组和良性组,差异有统计学意义（P＜0.05）;卵巢癌组miR-29c、miR-133b及miR-1水平均与分化程度有关,miR-29c水平与临床分期及淋巴结转移有关,而miR-133b亦与淋巴结转移有关,差异均有统计学意义（P＜0.05）;卵巢癌miR-29c水平与miR-133b和miR-1均呈负相关（r=-0.541、-0.361）,miR-133b与miR-1呈正相关（r=0.447）,差异均有统计学意义（P＜0.05）。结论 卵巢癌患者组织中miR-29c呈高表达,miR-133b及miR-1呈低表达,与临床病理学特征有关,且在卵巢癌诊断中有一定的价值,可用于辅助卵巢癌的诊断和病情评估。     

血清miR-21和miR-34a与晚期胃癌患者Folfox化疗方案化疗疗效的关系研究

目的 探讨晚期胃癌患者Folfox方案化疗前后血清miR-21和miR-34a水平变化及其与化疗疗效的关系。方法 以在我院接受Folfox方案化疗的45例晚期胃癌患者为研究对象。采用Real-time PCR检测化疗前后miR-21和miR-34a水平,分析miR-21和miR-34a水平与化疗疗效和患者预后的关系,采用受试者工作曲线(ROC)评估miR-21和miR-34a对化疗疗效的评估。结果 化疗后,部分缓解6例(13.33%)、疾病稳定10例(22.22%)、疾病进展29例(64.44%),客观缓解率为13.33%,疾病控制率为35.56%,中位生存期为8.1个月。化疗后miR-21水平下调,而miR-34a水平上调,差异有统计学意义(P＜0.05)。化疗有效组miR-21水平低于无效组,而miR-34a水平高于无效组,差异有统计学意义(P＜0.05)。miR-21与化疗疗效呈负相关,miR-34a与之呈正相关(r_s=-0.431,0.504,P＜0.05)。miR-21低水平患者中位生存期7.6个月,而高水平患者为6.0个月;miR-34a低水平患者中位生存期5.5个月,而高水平患者为8.3个月,Log-Rank检验显示,miR-21低水平患者中位生存期大于高水平患者(P＜0.05),miR-34a高水平患者中位生存期大于低水平患者(P＜0.05)。miR-21和miR-34a联合评估化疗疗效的曲线下面积为0.865、灵敏度为80.9%、特异度为89.8%。结论 血清miR-21和miR-34a与晚期胃癌化疗疗效和患者中位生存期相关。     

血清miR-30a水平与乳腺癌化疗敏感性的相关性

目的:探讨血清miR-30a水平对局部进展期乳腺癌患者新辅助化疗敏感性的预测价值.方法:纳入145例TNM分期为II-III期乳腺癌患者,根据实体瘤疗效评价标准(RECIST 1.0)将患者分为化疗敏感组(103例)和化疗抵抗组(42例),通过实时荧光定量PCR检测患者初次化疗前血清miR-30a水平,并与健康人群进行...     

胃癌组织中miR-200a、miR-200b和miR-429的表达及临床意义北大核心CSCD

0 引言 胃癌是消化系统常见恶性肿瘤之一,2006年中国肿瘤发病和死亡资料分析显示,无论城市还是农村,胃癌的发病率和死亡率均居恶性肿瘤第二位,已成为我国今后恶性肿瘤防控的重点[1]。目前,胃癌的病因尚不明确,加之滞后的临床表现和诊断,以手术为主、放化疗为辅的综合治疗手段亦未能显著提高患者的5年生存率[2]。所以,探寻胃癌新特异性的分子标志物,为其早期诊断开辟新途径具有重要意义。     

原癌基因miR-21与寿命的相关性研究

目的探讨原癌基因miR-21在不同年龄段人群血清中表达量的变化及与寿命的关系。方法选取2014年1月至2016年12月间首都医科大学附属北京友谊医院体检及住院的29例不同年龄段人群为研究对象,其中青年组10例,中老年组9例,长寿组10例,提取3组人员的血清样品,利用实时荧光定量聚合酶链反应(PCR)法检测原癌基因miR-21表达水平,判断miR-21在不同年龄段人群血清中的表达量情况。结果长寿组人员血清中miR-21相对表达量为(0.82±0.39),显著低于中老年组的(1.43±0.51),差异有统计学意义(P<0.05)。将肌酐清除率、EF值和血脂水平分别与miR-21相对含量进行比对发现,不同年龄段miR-21相对含量趋势与血脂水平近似,长寿组人群中血脂水平较中老年组人群略有下降,但差异无统计学意义(P>0.05)。结论原癌基因miR-21可能在长寿人群中表达量减低,抑制恶性肿瘤发生,其表达量与血脂有相关性,有望成为寿命相关性基因之一。     

miR-10a在肿瘤中的研究进展

miR-10a作为微小RNA（miRNA）家族的成员之一,属于miR-10家族,定位于17号染色体短臂的HOXB4与HOXB5基因之间.miR-10a在多种人体肿瘤中异常表达,与肿瘤的发生、发展及预后密切相关.文章就miR-10a与多种肿瘤的关系进行综述.     

血清miR-367、miR-383表达水平与宫颈癌根治术后复发及预后的相关性

目的:探讨血清微小RNA-367(microRNA-367,miR-367)、微小RNA-383(microRNA-383,miR-383)表达水平与宫颈癌根治术后复发及预后的相关性.方法:选取2012年01月至2014年12月在本院行宫颈癌根治术的114例患者为研究对象,记录患者年龄、肿瘤大小、病理类型、病理分级、临...     

肝细胞癌组织中lncRNA H19、miR-200a表达变化与临床预后的相关性分析

目的:观察肝细胞癌（hepatocellular carcinoma,HCC）组织中lncRNA H19、miR-200a表达情况,并探讨其与HCC患者临床病理特征及预后的关系。方法:选取57例HCC患者经手术切取的HCC组织和相应癌旁组织（≥癌灶边缘5 cm）,以及60例因肝血管瘤行手术切除的周围正常肝组织。采用qRT-PCR法检测组织中lncRNA H19和miR-200a表达水平;分析其与HCC患者临床病理特征及5年总生存率（overall survival,OS）的关系。结果:HCC组织中lncRNA H19表达水平明显高于癌旁组织和正常肝组织（P＜0.05）;HCC组织中miR-200a表达水平显著低于癌旁组织和正常肝组织（P＜0.05）。HCC组织中lncRNA H19、miR-200a表达与HCC患者分化程度、TNM分期、AFP值及是否侵袭转移有关（P＜0.05）。HCC组织中lncRNA H19表达与miR-200a表达呈负相关（P＜0.05）。HCC患者lncRNA H19低表达5年OS明显高于高表达（P＜0.05）;HCC患者miR-200a高表达5年OS显著高于低表达（P＜0.05）。分化程度、TNM分期、lncRNA H19及miR-200a表达均是影响HCC患者预后的独立危险因素（P均＜0.05）。结论:HCC组织中lncRNA H19表达上调、miR-200a表达下调,二者异常表达与病情程度及5年OS关系密切,可能相互作用参与HCC发展。     

Expression and Clinical Significance of miR-152 and CYFRA21-1 in Ovarian Cancer Tissues

To investigate the expression and clinical significance of miR-152 and CYFRA21-1 in ovarian cancer (OC) tissues. Seventy-four OC patients diagnosed in our hospital from March 2016 to April 2019 (research group, RG) and 30 patients with benign ovarian tumor at the same time (control group, CG) were collected as research objects in this experiment. qRT-PCR and ELISA were used to detect and observe the expression levels of miR-152 in patient tissues and CYFRA21-1 in serum. ROC curves were drawn to analyze the diagnostic value of miR-152 and CYFRA21-1 in OC. The clinicopathological correlation analysis was observed, Pearson was used to examine the correlation between the expression levels of miR- 152 and CYFRA21-1 and carcinoembryonic antigen (CEA), and the 3-year survival rate of patients was observed according to the high and low expression of miR-152 and CYFRA21-1. qRT-PCR and ELISA showed that the miR-152 expression in the RG was dramatically lower than that in the CG, while CYFRA21-1 (μg/L) was remarkably higher than that in the CG (p < 0.05). ROC was drawn based on the miR- 152 and CYFRA21-1 expression levels. The area under miR-152 curve was 0.724 (p < 0.05), and the area under CYFRA21-1 curve was 0.714 (p < 0.05). The expression levels of miR-152 and CYFRA21-1 were relevant to lymph metastasis, differentiation degree and pathological stage of OC patients (p < 0.05). Pearson test analysis identified that miR-152 and CYFRA21-1 were positively correlated with CEA (p < 0.001). The 3-year overall survival rate of miR-152 Low Expression Group (LEG) was 61.54%, that of high expression group (HEG) was 84.85%, that of CYFRA21-1 LEG was 83.75%, and that of HEG was 60.54%. miR-152 shows low expression in the tissues of patients and CYFRA21-1 shows high expression in serum, and both indexes have good diagnostic efficacy. The higher the miR-152 expression is, the higher the survival rate is, while the higher the CYFRA21-1 expression is, the lower the survival rate is.     

miR-200a Overexpression in Advanced Ovarian Carcinomas as a Prognostic Indicator

Background: miR-200a expression is frequently altered in numerous cancers. The aim of the present studywas to determine the role of microRNA-200a in advanced ovarian carcinomas. Materials and Methods: Wemeasured miR-200a expression in 72 matched normal ovarian tissues and advanced ovarian carcinomas, andalso two ovarian carcinoma cell lines (SKOV3 and SKOV3.ip1 - the latter being more invasive and metastaticthan the parental SKOV3) by stem-loop real-time RT-PCR based on TaqMan microRNA assay using U6 as areference. Levels of miR-200a expression were compared by disease stage, tumor grade, histology, and lymphnode involvement. To evaluate the role of microRNA-200a, cell proliferation and invasion of SKOV-3 andSKOV-3.ip1 were analyzed with miR-200a inhibitor/mimic transfected cells. Results: Of 72 paired samples,65 cancer tissues overexpressed microRNA-200a greater than two fold in comparison with matched normalepithelium. Specifically, patients with lymph node metastasis showed significant elevation. The level correlatedwith clinicopathological features, including high tumor grade, late disease stage, most notably with lymph nodemetastasis, but not with tumor histology. In addition, SKOV-3.ip1 cells also overexpressed miR-200a comparedwith SKOV-3, and miR-200a inhibitor transfected SKOV-3.ip1 cells showed significant reduction in cellularproliferation and invasion, while a miR-200a mimic stimulated the opposite behavior. Conclusions: We providedefinitive evidence that miR-200a is up-regulated in a significant proportion of advanced ovarian carcinomas,and that elevated miR-200a expression facilitates tumor progression. Our findings support the notion that miR-200a is an onco-microRNA for ovarian cancer, and elevation is a useful potential diagnostic indicator. This studyalso provides a solid basis for further functional analysis of miR-200a in advanced ovarian cancer.     

Identification of Serum MicroRNA-21 as a Biomarker for EarlyDetection and Prognosis in Human Epithelial Ovarian Cancer

Recent investigations have confirmed up-regulation of serum miR-21 and its diagnostic and prognostic valuein several human malignancies. In this study, we examined serum miR-21 levels in epithelial ovarian cancer(EOC) patients, and explored its association with clinicopathological factors and prognosis. The results showedsignificantly higher serum miR-21 levels in EOC patients than in healthy controls. In addition, increased serummiR-21 expression was correlated with advanced FIGO stage, high tumor grade, and shortened overall survival.These findings indicate that serum miR-21 may serve as a novel diagnostic and prognostic marker, and be usedas a therapeutic target for the treatment of EOC.     

miR-200c inhibits breast cancer proliferation by targeting KRAS

The microRNA, miR-200c, is involved in the tumorigenesis and progression of a variety of cancers. The purpose of this study was to investigate the expression, mechanism and prognostic roles of miR-200c in breast cancer. We found that miR-200c was downregulated in both breast cancer tissue and cell lines using quantitative real-time PCR (qRT-PCR). In situ hybridization (ISH) and microarrays showed that low miR-200c expression was associated with poor patient overall survival (OS) and disease free survival (DFS). We used luciferase reporter plasmids to find that miR-200c inhibited the AKT and ERK pathways by directly targeting KRAS. Repression of KRAS by miR-200c suppressed the proliferation and survival of breast cancer cells in vitro and in vivo. miR-200c also had an anti-tumor effect by negatively regulating KRAS in a xenograft mouse model. Our findings provide clues regarding the role of miR-200c as a tumor suppressor in breast cancer through the inhibition of KRAS translation both in vitro and in vivo. miR-200c could be a potential therapeutic target in breast cancer.     

miR-21在食管癌中的研究进展

食管癌是一种常见的恶性肿瘤,发病率高,预后差.miR-21在食管癌患者的癌组织、血液、唾液中均表达上调,其表达异常与食管癌发生发展密切相关.miR-21主要通过调控与肿瘤相关的靶基因发挥作用,尤其在食管癌的诊断、治疗及预后中有重要的临床应用价值.     

miR-200a在肝癌干细胞中的差异表达及其作用

目的:分离肝癌细胞系MHCC97-H中肝癌干细胞并分析miR-200a在肝癌干细胞和非肝癌干细胞亚群中的表达差异,探讨miR-200a的表达水平与肝癌干细胞之间的关系.方法:利用流式细胞荧光激活分选法从MHCC97-H中分选出肝癌干细胞(liver cancer stem cells,LCSCs)和非肝癌干细胞(non-liver canc-er stem cells,non-LCSCs)两个亚群;采用real-time PCR检测miR-200a在两个亚群中的表达差异;在MH-CC97-H中瞬时转染miR-200a-mimic,检测LCSCs亚群比例的变化.结果:LCSCs亚群占总体细胞的百分比为3.56％;LCSCs亚群细胞中miR-200a的表达明显低于non-LCSCs亚群(P＜0.05);上调miR-200a后LCSCs亚群细胞比例为1.24％.结论:miR-200a在LCSCs亚群细胞中明显低表达,上调miR-200a后LCSCs亚群细胞比例明显降低,提示miR-200a能够调控肝癌干细胞的比例.通过调控miR-200a的表达,可以降低LCSCs亚群细胞比例,从而为肝癌的治疗提供新的思路.     

基质金属蛋白酶与卵巢癌发生、发展关系的研究进展

卵巢癌是死亡率最高的女性生殖系统恶性肿瘤,研究发现基质金属蛋白酶在卵巢癌中大量表达,其与卵巢癌的发生、发展、侵袭及转移密切相关。同时研究发现,基质金属蛋白酶与基质金属蛋白酶组织抑制物两者间平衡的破坏可能与肿瘤的恶性表型相关,因此本文探讨基质金属蛋白酶在卵巢癌中的作用机制,将有助于研制有效的抗肿瘤药物,提高卵巢癌患者的生存率。     

结肠癌患者血清中IL-21水平分析及临床意义的研究

目的:探讨结肠癌患者血清中IL-21水平和患者病理状态及相关因素之间的关系.方法:采用双抗体夹心ABC-ELISA法,随机选取结肠癌患者40例测定结肠癌患者血清IL-21和IFN-γ的浓度;结合患者免疫平衡状态的变化分析IL-21与IFN-γ年龄、临床分期、病理类型、浸润深度、肿瘤大小和淋巴结转移等因素的相关水平的关系.结果:40例结肠癌患者血清中的IL-21水平与IFN-γ水平之间呈正相关关系;随着患者临床分期的进展、肿瘤浸润深度的增加、肿瘤体积增大及淋巴结转移,IL-21分泌水平虽有不同程度升高,但血清中IFN-γ分泌量未相应增加,结肠癌患者体内免疫平衡向TH2方向漂移.结论:结肠癌患者体内IL-21相对不足,未能有效刺激IFN-γ的分泌增加,从而导致患者体内免疫平衡状态失衡.     

miRNA21/PDCD4环路在卵巢癌组织中的表达

目的探讨miRNA21/PDCD4环路在卵巢肿瘤中的作用及其临床意义。方法采用qRT-PCR和Western blot方法检测miRNA21和PDCD4在108例卵巢癌患者、67例交界性病变、75例良性病变和35例正常组织中的表达情况。结果miRNA21在卵巢癌组织中的表达水平是正常卵巢组织的 12.3 倍(P＜0.01);在交界性病变组织中的表达水平是正常卵巢组织的 7.8 倍 (P＜0.01);在良性病变组织中的表达水平是正常卵巢组织的 3.6 倍 (P＜0.05)。PDCD4蛋白含量在卵巢癌组织中的表达明显低于交界性病变组织,交界性病变组织低于良性病变组织,良性病变组织低于正常卵巢组织,两两相比差异均具有统计学意义（P<0.05）,正常卵巢组织与卵巢癌和交界性病变组织中PDCD4蛋白含量相比差异有统计学意义（P<0.01）。结论miRNA21/PDCD4环路异常在卵巢癌发生中具有重要的作用。     

Association between Genetic Polymorphisms of miR-1307, miR- 1269, miR-3117 and Breast Cancer Risk in a Sample of South East Iranian Women

Introduction: MicroRNAs (miRNAs) play an essential role in the susceptibility and development of cancer cells. Objective: Examining the dependency of breast cancer risk with genetic polymorphisms of miR-1307, miR-1269, and miR-3117 in a sample of Iranian women (southeast region). Methods: The case-control study consisted of 520 individuals (260 diagnosed BC patients, 260 healthy individuals). The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping of miR-1307 rs7911488, miR-1269 rs73239138, and miR-3117 (rs4655646 and rs7512692) polymorphisms. Results and Conclusion: This study provided evidence that miR-1307 rs7911488 polymorphism significantly reduced the risk of BC in heterozygous AG genotype, as well as dominant (AG+GG) genotype and G allele. A significant correlation was found between dominant (AA+AG) genotype, the A allele and protection against BC due to miR-1269 rs73239138 in the sample of study. In contrast, our findings suggested that AG genotype and G allele of miR-3117 rs4655646 polymorphism could increase BC’s susceptibility among the southeastern Iranian females. The miR-3117 rs7512692 variant also increased the risk of BC in codominant, dominant and recessive models, as well as the T allele. The possible dependency of miR-1307, miR-1269, and miR-3117 variants with patients’ clinicopathological characteristics and BC was also studied. It was concluded that there is a correlation between miR-3117 rs7512692 variant and tumor grade (p=0.031); also, a correlation between miR-1269 rs73239138 variant and progesterone receptor status (p=0.006). The current investigation revealed that miR-1307, miR-1269, and miR-3117 polymorphisms might play a crucial role in the Iranian population’s vulnerability to BC.